Regulus Therapeutics sets terms for $50 million IPO
Regulus Therapeutics, a biopharmaceutical company focused on developing drugs that target microRNA, announced terms for its IPO on Friday. The San Diego, CA-based company plans to raise $50 million by offering 4.5 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Regulus Therapeutics would command a market value of $239 million. Regulus Therapeutics, which was founded in 2007 and booked $14 million in sales for the 12 months ended June 30, 2012, plans to list on the NASDAQ under the symbol RGLS. Lazard Capital Markets, Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.